eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2021
vol. 25
 
Share:
Send email
Share:
abstract:
Original paper

Forkhead box M1 over-expression and dachshund homolog 1 down- -regulation as novel biomarkers for progression of endometrial carcinoma in Egyptian patients

Abeer M. Hafez
1
,
Ola A. Harb
1
,
Waleed M. Etman
2
,
Basem Hamed
2
,
Alfred E Namour
3
,
Lobna A. Abdelaziz
4

  1. Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  2. Department of Gynecology and Obstetrics, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  3. Medical Oncology Department, National Cancer Institute, Egypt
  4. Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Contemp Oncol (Pozn) 2021; 25 (2): 107–117
DOI: https://doi.org/10.5114/wo.2021.106697
Online publish date: 2021/06/01
View full text Get citation
 
PlumX metrics:
Introduction
Forkhead box M1 (FOXM1) is considered as a novel anti-cancer target, because it has many essential functions such as mitosis regulation, cell cycle transition, and other carcinogenesis signaling pathways. Dachshund homolog 1 (DACH1) is a member of the Sno/Ski co-repressor family.

Material and methods
Expression of DACH1 has been detected in many cancers. Patients and pathologic specimens: 50 patients with endometrial cancer (EC) were included in the study: ten specimens of normal endometrium and twenty specimens of endometrial hyperplasia. All samples underwent processing to investigate FOXM1 and DACH1 expression using immunohistochemistry.

Results
FOXM1 expression was detected in EC tissues more than normal endometrium and endometrial hyperplasia tissues (p = 0.001) and 0.01. Increased FOXM1 expression was positively associated with larger tumor size (p = 0.002), high grade (p = 0.004), myometrial invasion, presence of lymph node metastases, higher Federation of Gynecology and Obstetrics (FIGO) stage (p < 0.001), and worse progression‑free survival (PFS) and overall survival (OS) rates. The expression of DACH1 was lower in EC cells than normal endometrium and endometrial hyperplasia tissues (p = 0.071) and 0.252. Low DACH1 expression was associated with high grade (p = 0.001), presence of lymph node metastases (p = 0.49), higher FIGO stage (p = 0.022), and unfavorable PFS and OS rates (p = 0.037). We found an inverse association between expression of FOXM1 and DACH1 in EC tissues and in non-neoplastic endometrial tissues (p = 0.007).

Conclusions
FOXM1 over-expression and DACH1 down-regulation in EC were related to poor clinical and pathological parameters and unfavorable prognosis.

keywords:

endometrial cancer, FOXM1 and DACH1, prognosis, immunohistochemistry
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.